The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy

Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy (ACT) based on ex vivo expanded peripheral CTLs, tumor infiltrating lymphocytes (TILs), gene-engineered TCR- and chimeric antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu, Zhang, Hui, He, You-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658873/
https://www.ncbi.nlm.nih.gov/pubmed/31379815
http://dx.doi.org/10.3389/fimmu.2019.01574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658873/
https://www.ncbi.nlm.nih.gov/pubmed/31379815
http://dx.doi.org/10.3389/fimmu.2019.01574

Ejemplares similares